Only multiple autoantibodies to islet cells (ICA), insulin, GAD65, IA-2 and IA-2β predict immune-mediated (type 1) diabetes in relatives
- Noel Maclaren(corresponding author),
- Michael Lan,
- Regis Coutant,
- Desmond Schatz,
- Janet Silverstein,
- Andrew Muir
- Louisiana State University Health Sciences Center,
- University of Florida,
- ,
- University of South Florida,
- Humana Hospital,
- SUNY Buffalo
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewSustainable Development Goals
- SDG 3 Good Health and Well
Abstract
<p>We report here our prospective study of 15,224 non-diabetic, first- degree relatives of probands with immune-mediated (type 1) diabetes (IMD), of which 135 were found to eventually develop diabetes. We determined islet cell, insulin, GAD65, insulinoma-associated antigen-2 and 2β autoantibodies (ICA, IAA, GAD65A, IA-2A and IA-2βA), on the first available serum samples. The latter three autoantibodies were however assayed on subsets of the relatives with and without ICA, IAA and/or GAD65A, plus most of the relatives who developed diabetes. Of the relatives who progressed to diabetes, 94% had at least one of these autoantibodies on the first screening, while ICA proved to be the most sensitive single marker (sensitivity 74%). Risk of diabetes was however negligible when ICA was found in the absence of the others (5- year risk=5.3%), but increased dramatically whenever two or more autoantibodies were present (5-year risk=28.2% and 66.2%, respectively). The most predictive combination of markers was ICA plus IA-2A and/or IA-2β A. Loss of first phase insulin release to IVGTT also occurred only in those ICA- positive relatives who had one or more of the other autoantibodies. The data suggests that significant β-cell damage is seen only when the underlying autoimmunity has spread to multiple antigenic islet cell determinants. Combinations of the autoantibodies occurred most often in relatives with the highest risk HLA-DR/DQ phenotypes. These data document that only relatives positive for at least two or more of these five autoantibodies are at significant risk of diabetes themselves. Intervention trials for the prevention of type 1 diabetes could be designed based on testing for these autoantibodies alone, without the need for HLA typing and IVGTT testing.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 279-287 (9 pages)Journal (Volume, Issue Number)
Journal of Autoimmunity (Volume 12, Issue 4)Publication milestones
- Published - 06/1999
Publication status
Published - 06/1999
ISSN
0896-8411Publication IDs
- Scopus: 0033020127
- PubMed: 10330299
Publication metrics
Metrics
SciVal
citations
99
Fractional count
1
Fractional count
0.06
Fractional count
15
Fractional count
0.94
Fractional count
1
Fractional count
1
SciVal
FWCI
1.96
SciVal
Author count
16
SciVal
Paper percentile
93
SciVal
Top percentile
10
PlumX, opens in new tab
Captures
23
Citation count
115
Funding Details
This study was supported by grants RO1 HD 19469; GCRC MO1 RR00082 from the National Institutes of Health; American Diabetes Association Mentor Award and a gift-in-aid from Sydney Kriser.
FundersFunding number
NIH
-ADA
-NICHD
R01HD019469
